17.00

2.29% 0.38

After Hours: 16.90 -0.10 -0.59%

Summit Therapeutics Inc (SMMT)

Overview News Price History Option Chain Financials Why SMMT Down? Discussions Forecast

Summit Therapeutics Inc stock is traded at $17.00, with a volume of 5.25M. It is up +2.29% in the last 24 hours and down -23.01% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Previous Close:

$16.62

Open:

$16.58

24h Volume:

5.25M

Relative Volume:

1.52

Market Cap:

$13.19B

Revenue:

$220.00K

Net Income/Loss:

$-1.08B

P/E Ratio:

-11.77

EPS:

-1.4448

Net Cash Flow:

$-326.53M

1W Performance:

+7.26%

1M Performance:

-23.01%

6M Performance:

-4.60%

1Y Performance:

-34.24%

1-Day Range:

$15.89

$17.13

1-Week Range:

$15.89

$17.96

52-Week Range:

$13.83

$30.98

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name

Summit Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

305-203-2034

Address

601 BRICKELL KEY DRIVE, MIAMI

Employee

265

Twitter

@summitplc

Next Earnings Date

2026-05-07

Latest SEC Filings

SMMT's Discussions on Twitter

Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SMMT Summit Therapeutics Inc	17.00	12.90B	220.00K	-1.08B	-326.53M	-1.4448
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-08-26	Initiated	Stifel	Buy
Mar-16-26	Downgrade	Jefferies	Buy → Hold
Dec-17-25	Upgrade	Barclays	Underweight → Equal Weight
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Underweight
Sep-04-25	Initiated	Guggenheim	Buy
Aug-19-25	Initiated	Piper Sandler	Neutral
Jul-01-25	Initiated	UBS	Buy
Jun-11-25	Initiated	Leerink Partners	Underperform
Mar-26-25	Upgrade	Citigroup	Neutral → Buy
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-12-25	Initiated	Evercore ISI	Outperform
Feb-28-25	Initiated	Goldman	Buy
Jan-08-25	Initiated	Truist	Buy
Dec-11-24	Initiated	Wells Fargo	Overweight
Dec-06-24	Initiated	Jefferies	Buy
Nov-04-24	Initiated	JMP Securities	Mkt Outperform
Sep-27-24	Downgrade	Citigroup	Buy → Neutral
Aug-12-24	Initiated	H.C. Wainwright	Buy
May-07-24	Initiated	Citigroup	Buy
Mar-26-24	Initiated	Stifel	Buy
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy
Feb-13-18	Initiated	BTIG Research	Buy
Jan-04-18	Initiated	SunTrust	Buy
Dec-01-17	Resumed	H.C. Wainwright	Buy
Nov-16-16	Reiterated	RBC Capital Mkts	Outperform
Oct-05-16	Reiterated	Needham	Buy
Sep-16-16	Initiated	H.C. Wainwright	Buy
Mar-30-15	Initiated	Needham	Buy
Mar-30-15	Initiated	Oppenheimer	Outperform

View All

Summit Therapeutics Inc Stock (SMMT) Latest News

10:06 AM

Bernstein reiterates Summit Therapeutics stock Underperform rating By Investing.com - Investing.com Canada

10:06 AM

May 25, 2026